Is Coral Labs. overvalued or undervalued?

As of 28 October 2025, Coral Labs. has moved from an attractive to a very attractive valuation grade. The company appears to be undervalued, given its strong financial ratios, including a PE ratio of 9.46, an EV to EBITDA ratio of 4.01, and a Price to Book Value of 0.87. These figures suggest that Coral Labs. is trading at a significant discount compared to its peers.
In comparison to its industry peers, Coral Labs. has a much lower PE ratio than Sun Pharma. Industries, which stands at 35.35, and Divi's Lab, which is at 74.05, indicating that Coral Labs. is undervalued relative to these companies. Additionally, its PEG ratio is 0.00, further emphasizing its attractive valuation. Despite recent stock performance lagging behind the Sensex, with a year-to-date return of -35.85% compared to the Sensex's 8.30%, the underlying fundamentals suggest that Coral Labs. presents a compelling investment opportunity.